Methods of treating gastrointestinal tract disorders using sodium channel modulators
View Patent ↗The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat a gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.
1. A method for treating a functional gastrointestinal tract disorder, which comprises administering to an individual in need thereof a therapeutically effective amount of ambroxol or a pharmaceutically acceptable salt, enantiomer, analog, ester, amide, prodrug, metabolite, or derivative thereof wherein said functional gastrointestinal tract disorder is selected from the group consisting of irritable bowel syndrome, slow-transit constipation, non-ulcer dyspepsia, an evacuation disorder and functional dysphasia.
2. The method of claim 1 , wherein said functional gastrointestinal tract disorder is irritable bowel syndrome.
3. The method of claim 1 , wherein said functional gastrointestinal tract disorder is slow-transit constipation.
4. The method of claim 1 , wherein said functional gastrointestinal tract disorder is non-ulcer dyspepsia.
5. The method of claim 1 , wherein said functional gastrointestinal tract disorder is an evacuation disorder.
6. The method of claim 1 , wherein said functional gastrointestinal tract disorder is functional dysphagia.
7. The method of claim 1 , wherein said ambroxol or a pharmaceutically acceptable salt, enantiomer, analog, ester, amide, prodrug, metabolite, or derivative thereof is administered orally, transmucosally, sublingually, buccally, intranasally, transurethrally, rectally, by inhalation, topically, transdermally, parenterally, or intrathecally.
8. The method of claim 1 , wherein said ambroxol or a pharmaceutically acceptable salt, enantiomer, analog, ester, amide, prodrug, metabolite, or derivative thereof is administered concurrently with an additional active agent.
9. The method of claim 8 , wherein the additional active agent is selected from the group consisting of an antispasmodic, a tricyclic antidepressant, duloxetine, venlafaxine, a monoamine reuptake inhibitor, a spasmolytic, an anticholinergic, gabapentin, pregabalin, a substituted aminomethyl-phenyl-cyclohexane derivative, a 5-HT 3 antagonist, a 5-HT 4 antagonist, a β3 adrenergic agonist, a neurokinin receptor antagonist, a bradykinin receptor antagonist, a nitric oxide donor, and derivatives thereof.